Testing for antibiotic resistance and susceptibility where staph infections are concerned is an ongoing concern in healthcare and a topic that is being discussed this week at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) meeting in San Francisco. Currently the only rapid test cleared by FDA to differentiate methicillin resistant Staphylococcus aureus (MRSA) infections from methicillin susceptible Staphylococcus aureus (MSSA) infections is the KeyPath MRSA/MSSA blood culture test, from MicroPhage (Longmont, Colorado), which provides same-day results for these deadly infections. Read More
